Hilliard L Kutscher1,2,3, Gene D Morse1,4, Paras N Prasad2, Jessica L Reynolds5. 1. Translational Pharmacology Research Core, NYS Center of Excellence in Bioinformatics and Life Sciences, University at Buffalo, Buffalo, New York, 14203, USA. 2. Institute for Lasers, Photonics and Biophotonics, University at Buffalo, Buffalo, New York, 14260, USA. 3. Department of Anesthesiology, University at Buffalo, Buffalo, New York, 14203, USA. 4. Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, 14214, USA. 5. Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, 14203, USA. Jlr8@buffalo.edu.
Abstract
PURPOSE: An in vitro dynamic pharmacokinetic (PK) cell culture system was developed to more precisely simulate physiologic nanoparticle/drug exposure. METHODS: A dynamic PK cell culture system was developed to more closely reflect physiologic nanoparticle/drug concentrations that are changing with time. Macrophages were cultured in standard static and PK cell culture systems with rifampin (RIF; 5 μg/ml) or β-glucan, chitosan coated, poly(lactic-co-glycolic) acid (GLU-CS-PLGA) nanoparticles (RIF equivalent 5 μg/ml) for 6 h. Intracellular RIF concentrations were measured by UPLC/MS. Antimicrobial activity against M. smegmatis was tested in both PK and static systems. RESULTS: The dynamic PK cell culture system mimics a one-compartment elimination pharmacokinetic profile to properly mimic in vivo extracellular exposure. GLU-CS-PLGA nanoparticles increased intracellular RIF concentration by 37% compared to free drug in the dynamic cell culture system. GLU-CS-PLGA nanoparticles decreased M. smegmatis colony forming units compared to free drug in the dynamic cell culture system. CONCLUSIONS: The PK cell culture system developed herein enables more precise simulation of human PK exposure (i.e., drug dosing and drug elimination curves) based on previously obtained PK parameters.
PURPOSE: An in vitro dynamic pharmacokinetic (PK) cell culture system was developed to more precisely simulate physiologic nanoparticle/drug exposure. METHODS: A dynamic PK cell culture system was developed to more closely reflect physiologic nanoparticle/drug concentrations that are changing with time. Macrophages were cultured in standard static and PK cell culture systems with rifampin (RIF; 5 μg/ml) or β-glucan, chitosan coated, poly(lactic-co-glycolic) acid (GLU-CS-PLGA) nanoparticles (RIF equivalent 5 μg/ml) for 6 h. Intracellular RIF concentrations were measured by UPLC/MS. Antimicrobial activity against M. smegmatis was tested in both PK and static systems. RESULTS: The dynamic PK cell culture system mimics a one-compartment elimination pharmacokinetic profile to properly mimic in vivo extracellular exposure. GLU-CS-PLGA nanoparticles increased intracellular RIF concentration by 37% compared to free drug in the dynamic cell culture system. GLU-CS-PLGA nanoparticles decreased M. smegmatis colony forming units compared to free drug in the dynamic cell culture system. CONCLUSIONS: The PK cell culture system developed herein enables more precise simulation of human PK exposure (i.e., drug dosing and drug elimination curves) based on previously obtained PK parameters.
Authors: Michael W Hess; Kristian Pfaller; Hannes L Ebner; Beate Beer; Daniel Hekl; Thomas Seppi Journal: Methods Cell Biol Date: 2010 Impact factor: 1.441
Authors: Daniel L Clemens; Bai-Yu Lee; Min Xue; Courtney R Thomas; Huan Meng; Daniel Ferris; Andre E Nel; Jeffrey I Zink; Marcus A Horwitz Journal: Antimicrob Agents Chemother Date: 2012-02-21 Impact factor: 5.191
Authors: Admire Dube; Jessica L Reynolds; Wing-Cheung Law; Charles C Maponga; Paras N Prasad; Gene D Morse Journal: Nanomedicine Date: 2013-12-10 Impact factor: 5.307
Authors: Jeongyun Heo; Thomas A Sobiech; Hilliard L Kutscher; Lee Chaves; Dinesh K Sukumaran; Shanta Karki; Admire Dube; Paras N Prasad; Jessica L Reynolds Journal: Macromol Biosci Date: 2020-12-07 Impact factor: 4.979